[1]沈国鹏,梁春丽,葛庆平,等.5-氟尿嘧啶磁性固体脂质纳米粒制备工艺优化研究[J].郑州大学学报(工学版),2010,31(03):16-19.
 SHEN Guopeng,LIANG Chunli,GE Qingping,et al.Study on Optimization of 5-Fluorouracil Magnetic Solid Lipid Nanoparticles[J].Journal of Zhengzhou University (Engineering Science),2010,31(03):16-19.
点击复制

5-氟尿嘧啶磁性固体脂质纳米粒制备工艺优化研究()
分享到:

《郑州大学学报(工学版)》[ISSN:1671-6833/CN:41-1339/T]

卷:
31卷
期数:
2010年03期
页码:
16-19
栏目:
出版日期:
2010-03-01

文章信息/Info

Title:
Study on Optimization of 5-Fluorouracil Magnetic Solid Lipid Nanoparticles
作者:
沈国鹏梁春丽葛庆平等.
郑州大学,化工与能源学院,河南,郑州,450001, 河南省产品质量监督检验院,河南,郑州,450052, 郑州大学,药学院,河南,郑州,450001
Author(s):
SHEN Guopeng; LIANG Chunli; GE Qingping; etc
1.School of ChemicM Engineering and Energy,Zhengzhou University,Zhengzhou 450001,China;2.Henan Institute of ProductsQuality Supervision and Inspection。Zhengzhou 450052,China;3.School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China
关键词:
5-氟尿嘧啶 磁性固体脂质纳米粒 工艺优化 包封率
Keywords:
5-Fluorouracilmagnetic solid lipid nanoparticleoptimizationencapsulation rate
文献标志码:
A
摘要:
为提高5-氟尿嘧啶(5-Fu)制剂的疗效,降低毒副作用,以单硬脂酸甘油酯为载体,氢化大豆卵磷脂、泊洛沙姆为乳化剂,磁性纳米四氧化三铁为磁体,采用复乳-溶剂挥发法制备5-氟尿嘧啶磁性固体脂质纳米粒(5-Fu-MSLN).以包封率为考察指标,通过单因素实验和正交设计对制备工艺进行优化,所制备的5-Fu-MSLN包封率为58.35%.用透射电镜观察,磁性固体脂质纳米粒外观形态圆整,粒径分布均匀;在倒置的显微镜下观察,磁性固体脂质纳米粒体外磁响应性良好,实验结果表明,5-FU-MSLN是有希望的静脉给药靶向制剂.
Abstract:
To improve the therapeutic efficacy and reduce the toxicity of 5-Fluorouracil(5-FU),5-Flu-orouracil magnetic solid lipid nanoparticles(5-FU-MSLN)were prepared with a W/O/W double emulsionsolvent evaporation technique,using monostearin as the carrier,hydrogenated soybean lecithin and poloxameras emulsifier,magnetic Fe3 04 nanoparticles as magnets.With jhe index of encapsulation efficiency,the prep—aration process was optimized By single—factor test and orthogonal test.As a result,the encapsulation efficiency of 5-FU-MSLN was 58.35%.TEM presented 5-FU-MSLN as spherical particles.evenly distrib·uted:5一FU—MSLN were observed under the inverted microscope,of which vitro magnetic responsivenesswas good.Such magnetic solid lipid nanoparticles seem appropriate for vascular administration followed bydrug targeting.
更新日期/Last Update: 1900-01-01